Budesonid AstraZeneka contains the powerful not halogenated corticosteroid – budesonid, intended for treatment of bronchial asthma at patients for whom application of inhalers with spraying of medicinal substances compressed air or in the form of a dosage form of dry powder is inefficient or inexpedient.

for application to the babies and children sick with grain (a complication of a sharp viral upper respiratory tract infection that is also known as a laryngotracheobronchitis or podvyazochny laryngitis) that is the indication for hospitalization.

Structure

• active ingredient: budesonid;
for dispersion 0.25 mg of a budesonid contain
• 1 ml of suspension;
• other components: dinatrium edetat, sodium chloride, polysorbate 80, waterless citric acid, sodium citrate, water for injections.

Contraindication

Hypersensitivity to active ingredient or any of excipients.

Infection and an invasion it is frequent - stomatopharynx candidiasis, pneumonia (at patients with HOBL).

from the immune system - it is rare - hypersensitivity reactions of the immediate and delayed type, in particular rashes, contact dermatitis, a small tortoiseshell, a Quincke's disease and anaphylactic reaction.

from an endocrine system - it is rare - signs and symptoms of system effects of corticosteroids, in particular oppression of function of adrenal glands and a delay of growth rates.

Candidiasis in a stomatopharynx arises owing to adjournment of medicine on mucous. It is necessary to instruct the patient about need of rinsing of an oral cavity water after each inhalation of a maintenance dose to minimize this risk.

Route of administration

Dosage of the medicine Budesonid AstraZeneka needs to be adjusted depending on individual needs of the patient.

Scheme of a dosage.

dose Entered to the patient depends on the used equipment for dispersion. Time of dispersion and delivery depend on flow rate, the volume of the camera of the nebulizer and volume of filling. Speed of an air flow via the device used for dispersion has to be equal to 6-8 liters a minute. The suitable volume of filling for the majority of nebulizers is equal to 2-4 ml. The dosage of the medicine Budesonid AstraZeneka needs to be adjusted depending on individual needs of the patient. The dose should be lowered to the minimum necessary for maintenance of appropriate control of bronchial asthma. Children up to 12 years need to appoint the highest dose (2 mg/days) only at a heavy course of asthma and to a limited span.

Budesonid AstraZeneka is used only by means of the nebulizers suitable for this purpose.

Feature of application

Use during pregnancy or feeding by a breast

Pregnancy

that during pregnancy the adequate treatment of bronchial asthma was supported. As well as at use of other medicines during pregnancy, the advantage of application of a budesonid for mother should be weighed taking into account risks for a fruit.

Feeding by a breast

Budesonid gets into breast milk. However at application of therapeutic medicament doses Budesonid AstraZeneka is not expected any influence on the child who is on chest feeding. Budesonid AstraZeneka it is possible to apply when feeding by a breast.

Children

to children according to indications.

Ability to influence speed of response at control of motor transport or other mechanisms

Budesonid AstraZeneka does not influence or has insignificant impact on ability to steer vehicles and to work with other mechanisms.

Overdose

Budesonid AstraZeneka contains 0.1 mg/ml of dinatrium of the edetat that as it is proved, leads to narrowing of bronchial tubes if its level exceeds 1.2 mg/ml. The acute overdose by Budesonid AstraZeneka medicine, even at application of overdoses, will not make clinically significant problem.

Interaction to other medicines and other types of interactions

Metabolism of a budesonid happens mainly to participation of CYP3A4. It is expected that simultaneous application with CYP3A inhibitors, for example, with itrakonazoly, ketokonazoly, the inhibitors of HIV protease and medicines containing kobitsistat increases risk of development of systemic action of corticosteroids.

with powerful CYP3A inhibitors, except for cases when the advantage exceeds the increased risk of development of the system side effects connected with application of corticosteroids; in that case the condition of patients should be controlled concerning the system side effects connected with application of corticosteroids. In case of simultaneous use of Budesonid AstraZeneka medicine with antifungal medicines (such as itrakonazol and ketokonazol) the interval between use of these medicines has to be longer. It is possible to consider a question of reduction of a dose of a budesonid.

At the women who were at the same time accepting estrogen or hormonal contraceptives the concentration of a budesonid in blood plasma increased and the effect of corticosteroids amplified, however at application of a budesonid together with low doses of the combined oral contraceptives this effect was absent.

, the test on stimulation of secretion of AKTG intended for diagnostics of hypophysial insufficiency can yield false results (low values).

to Store

at a temperature above 30 °C. Not to freeze.

to Store

out of children's reach.

Containers should be stored in vertical position.

to Store containers in an envelope from a foil for protection against light influence.